{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:06:01Z","timestamp":1790139961118,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaccao.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:37:41Z","timestamp":1790138261000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Considerations of JAK Inhibitors in Patients With Hematologic Malignancies"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-6380","authenticated-orcid":false,"given":"Orly","family":"Leiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie E.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6649-3755","authenticated-orcid":false,"given":"Michael","family":"Garshick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2026.07.010_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular disease in myeloproliferative neoplasms: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.07.010_bib2","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1093\/eurheartj\/ehab447","article-title":"The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms","volume":"42","author":"Baldini","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.07.010_bib3","series-title":"Janus kinase (JAK) inhibitors: drug safety communication - FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death","year":"2021"},{"key":"10.1016\/j.jaccao.2026.07.010_bib4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaccao.2025.05.010","article-title":"Beyond thrombosis: Pulmonary hypertension and heart failure in patients with myeloproliferative neoplasms: JACC: cardiooncology state-of-the-art review","volume":"7","author":"Leiva","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.07.010_bib5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacbts.2019.05.013","article-title":"JAK2 (V617F) -Mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jaccao.2026.07.010_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jaccao.2026.07.010_bib7","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2026.07.010_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.07.010_bib9","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO-25-00809","article-title":"Ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease: final analysis from the randomized phase III REACH2 trial","volume":"43","author":"Mohty","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2026.07.010_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2026.07.010_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaccao.2026.07.010_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in Rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.07.010_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2026.07.010_bib14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10428194.2026.2639642","article-title":"Ruxolitinib and heart failure outcomes among patients with myelofibrosis","volume":"67","author":"Leiva","year":"2026","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaccao.2026.07.010_bib15","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/bloodadvances.2025016247","article-title":"Thrombosis, major bleeding, and mortality in 1079 patients with myelofibrosis: a matched population-based study","volume":"9","author":"Enblom","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2026.07.010_bib16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/ejh.70113","article-title":"Polycythemia vera and essential thrombocythemia: a nationwide population-based study on treatment patterns, vascular complications and survival","volume":"116","author":"Larsson","year":"2026","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaccao.2026.07.010_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106359","article-title":"Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted","volume":"183","author":"Benucci","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jaccao.2026.07.010_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/318364","article-title":"Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis","volume":"2015","author":"Garcia-Bermudez","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaccao.2026.07.010_bib19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/jha2.591","article-title":"Risk-adjusted safety analysis of the oral JAK2\/IRAK1 inhibitor pacritinib in patients with myelofibrosis","volume":"3","author":"Pemmaraju","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.jaccao.2026.07.010_bib20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaccao.2026.07.010_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","article-title":"Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I","volume":"15","author":"Mesa","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaccao.2026.07.010_bib22","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/bloodadvances.2025019152","article-title":"Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms","volume":"10","author":"Leiva","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2026.07.010_bib23","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/bloodadvances.2025018724","article-title":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms","volume":"10","author":"Leiva","year":"2026","journal-title":"Blood Adv"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326002929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326002929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:37:48Z","timestamp":1790138268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087326002929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S2666087326002929"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.07.010","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Considerations of JAK Inhibitors in Patients With Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}